Pfizer succeeds in Inlyta NICE appeal
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has reversed its recommendation on Pfizer's Inlyta (axitinib) after the company appealed the institute's previous final guidance. In its new draft guidance, NICE recommends the drug in some patients with advanced kidney cancer.